Shortening the Year Between First Symptom and ALS Diagnosis

Someone who develops ALS in the United States waits, on average, ten to sixteen months between the first symptom and a confirmed diagnosis.⁴ Median survival from symptom onset runs two to five years.¹ A quarter to half of the time a person has left gets spent inside a healthcare system that has not yet named what is wrong with them.

That year is rarely empty. It fills with orthopedic appointments, nerve conduction studies, and sometimes surgery for conditions the patient does not have. Between 27 and 61 percent of people with ALS receive a different diagnosis first.⁶ By the time the correct one arrives, roughly 60 percent already fail the eligibility criteria for the clinical trials that might have helped them.⁷

The delay closes doors in a specific order. Research access goes first because trial eligibility depends heavily on how far the disease has progressed. Multidisciplinary care, the one intervention with solid evidence behind it for extending survival, starts late and therefore has less time to work.¹¹ Families end up planning for a fatal illness on a shorter runway than they should have had.

The bottleneck sits in referral patterns more than in laboratory science. Patients wait three to six months before seeing anyone at all. Of those who do seek care, about 40 percent get sent to a specialist other than a neurologist.⁵ Each wrong turn costs weeks that this disease does not give back.

ALS Forward proposes work on three fronts: symptom-recognition outreach to the primary care and physical therapy clinicians who see these patients first, a navigation service that moves families from suspicion to a certified ALS clinic without them assembling the referral chain themselves, and direct financial help for the non-medical costs no payer covers. Sections 8 and 9 set out what each would cost and what we need from readers of this paper.

The federal authorities behind ACT for ALS expire on September 30, 2026, with reauthorization still pending in Congress.¹⁵

ALS destroys the motor neurons in the brain and spinal cord that carry signals to voluntary muscles, and the resulting weakness spreads outward from wherever it starts. Speech, swallowing, and eventually breathing fail. Most people die of respiratory complications within three years of their first symptom.¹

The CDC’s National ALS Registry, created by act of Congress in 2008, put the 2018 prevalence figure at roughly 30,000 Americans, and the agency notes that under-ascertainment means the true number may be closer to 35,000 at any one time.¹² More than 5,000 Americans are diagnosed each year.¹ Registry projections estimate cases will rise about 10 percent by 2030, driven mostly by an aging population.³

Most diagnoses land between ages 55 and 75, though the disease reaches people in their twenties and thirties.¹ Men are affected roughly 1.5 times as often as women. About 5 to 10 percent of cases run in families; the rest appear with no family history at all.¹ Military service carries a substantially higher risk, which is why the Department of Veterans Affairs treats ALS as a service-connected condition.¹⁴

The treatment picture explains why timing matters so much. Riluzole, approved in 1995, extends survival by roughly three months. Edaravone, approved in 2017 and available as an oral formulation since 2022, slows functional decline in some patients. Tofersen, approved in 2023, targets a genetic subtype that accounts for a small fraction of cases and requires genetic testing to identify. Relyvrio, approved in 2022, was pulled from the market in 2024 after its confirmatory Phase 3 trial failed to reproduce the earlier benefit.¹⁷ Every approved disease-modifying drug slows the rate of decline at best, and none restores function already lost. The date a patient starts one therefore determines how much function that patient keeps.

That leaves multidisciplinary care as the intervention with the strongest evidence behind it. Clinics that put a neurologist, respiratory therapist, speech-language pathologist, dietitian, therapists, and a social worker in one building on one day have been shown across multiple studies to extend survival and improve quality of life while reducing hospital admissions.¹¹ How fast a patient reaches one of those clinics can be changed locally.

A literature review covering twenty-one retrospective studies published between 1990 and 2020 found a typical interval of ten to sixteen months between first symptom and correct diagnosis.⁴ American figures sit in a similar band. Published evidence puts the U.S. average between 11.5 and 15 months, during which a patient sees three to four different health professionals before reaching an ALS specialist.⁶ A study of 304 patients found a median total diagnostic time of 11.5 months, with longer waits for patients over 60 and for those whose symptoms began in a limb instead of in speech or swallowing.⁶

Getting to a first appointment. Patients wait an average of three to six months before seeing any provider.⁵ Early ALS symptoms are quiet and easy to explain away. A foot drags a little, or a hand starts fumbling buttons. Most people put it down to age or a pinched nerve and wait to see whether it gets worse.

Getting to the right specialist. About 60 percent of patients are referred from primary care to a neurologist. The other 40 percent go elsewhere.⁵ Orthopedic surgery, neurosurgery, otolaryngology, physiotherapy, psychiatry, and rheumatology all appear regularly in the referral records of people who turn out to have ALS.⁴

Surviving the wrong diagnosis. In one study sample, slightly more than half of patients received an alternative diagnosis before the correct one, and estimates across the literature put initial misdiagnosis somewhere between 27 and 61 percent.⁶ Some of those patients undergo procedures they did not need. Spine surgeries, carpal tunnel releases, and immunotherapy courses all show up in the record.⁴

Where symptoms start substantially changes the timeline. Bulbar-onset ALS, which begins with slurred speech or difficulty swallowing, is typically diagnosed within seven to ten months, since those symptoms are unusual enough to trigger a neurology referral on their own. Limb-onset ALS, which is more common, takes ten to twenty-two months, because a weak grip looks like a hundred other things.⁵

Fixing this is a matter of referral behavior. A clinician who sees a 62-year-old with an unexplained foot drop needs to keep motor neuron disease on the list and send the patient to neurology.

Access to research

The clearest measurable cost is exclusion from clinical trials. An analysis of 38 randomized placebo-controlled ALS trials found that on average 59.8 percent of patients already fail eligibility criteria on the day they are diagnosed. Exclusion rates ranged from 14 percent to 95 percent depending on the trial. The most common disqualifiers were diagnostic certainty category, respiratory function measured by forced vital capacity, and required time since symptom onset.⁷

The authors argue that 59.8 percent understates the real figure, since enrollment usually happens six to nine months after diagnosis. By that point, 15 to 24 percent of the patients who would have qualified at diagnosis have died.⁷

The people who do enroll skew younger, more male, and slower-progressing than the general ALS population. Trial results therefore describe a subset of patients, and clinicians extrapolating those results to everyone else are working with thinner evidence than the publication implies.⁷ Every month shaved off the diagnostic delay moves patients back across the eligibility line.

The treatment window

A patient who begins riluzole at month twenty-two of their illness has fewer motor neurons left to protect than one who begins at month ten. Generic riluzole is inexpensive, and the case for starting early is uncontroversial among clinicians, but the prescription cannot be written until someone has made the diagnosis.

Time in multidisciplinary care

Specialized multidisciplinary clinics improve survival and quality of life, and the effect grows with the length of the relationship.¹¹ A patient who reaches one at month twelve gets more out of it than a patient who arrives at month twenty-four with respiratory involvement already advanced. Feeding tube placement, non-invasive ventilation, and communication technology all work better when introduced before the crisis that forces the decision.

Geography compounds the delay. The ALS Association’s 2026 clinic development grants highlighted rural Kansas, where many patients live more than 200 miles from the nearest certified clinic.¹⁸ The organization treats travel distance as a clinical variable instead of a logistical one, on the grounds that missed visits result in worse outcomes. Patients themselves cite travel and the length of clinic days as the main reasons they skip appointments.¹¹

Costs climb sharply the moment a diagnosis is confirmed, and the first year is the steepest stretch.

Researchers from the ALS Association and Avalere Health analyzed complete Medicare fee-for-service claims from 2017 through 2021, covering 11,260 people with claims consistent with an ALS diagnosis. Roughly two out of three Americans with ALS are covered by Medicare, either through age or through disability. Total medical costs in the first year after diagnosis averaged about $47,000. Out-of-pocket spending averaged $6,802, more than three times the $2,050 paid by comparable Medicare beneficiaries without ALS.⁸

The researchers were explicit that these figures undercount the true burden because Medicare claims data captures no non-medical spending. A wheelchair-accessible van does not appear. Neither does a bathroom renovation, a ramp, a widened doorway, or the income a spouse gives up.⁸

Studies that have measured those costs put them at roughly $17,889 per year in non-medical out-of-pocket spending plus about $14,682 in foregone income.¹⁰ Spending also rises steeply with disease stage. A 2024 analysis found average annual costs climbing from around $31,000 in early-stage disease to around $121,000 in late-stage disease.⁹

Medicare does not cover long-term custodial care. Private insurance generally does not either. In a 2020 ALS Focus survey of 440 people living with ALS and their caregivers, one in four reported borrowing money or going into debt because of treatment or caregiving costs.⁸ Community organizations end up covering the gap between what a family needs and what any payer will fund.

The person doing the work of ALS care is usually an unpaid family member. In a study of patient-caregiver pairs at a national ALS clinic, 70 percent of caregivers were women, 70 percent were spouses, and the median weekly caregiving load was 28 hours. The range ran from zero to 168 hours, which is to say some people were doing it continuously.¹³

Research on the health and well-being of ALS caregivers has found that a significant share stop working or cut their hours.¹² Most are caring for someone for the first time in their lives, learning to operate suction machines and ventilators and communication devices while also handling insurance appeals and equipment orders.

Support for caregivers tends to be the first thing cut when a program’s budget tightens, partly because the caregiver is not the patient and partly because respite care resists measurement. The consequence is easier to see in hindsight than in a budget line. When the caregiver stops functioning, the person with ALS moves into paid care or into a hospital, at several times the cost of the support that might have prevented it.

The ALS community has won real ground over the past decade. Advocacy eliminated the two-year Medicare waiting period that once applied to people with ALS on disability. Federal research funding rose substantially between fiscal years 2019 and 2021, and the VA’s service-connected designation gave veterans and survivors access to benefits.¹⁴

The Accelerating Access to Critical Therapies for ALS Act, enacted in December 2021, built infrastructure the field had lacked. Roughly 750 people with ALS have received investigational therapies through the NIH expanded access programs the law funded, most of them patients who would have failed standard trial criteria. The same law underwrote the Access for ALL in ALS natural history consortium, established an FDA grant program for rare neurodegenerative disease research, and created a public-private partnership spanning both agencies. A 2026 GAO report put total NIH and FDA awards under the law at about $276 million between fiscal years 2022 and 2025.¹⁶

Those authorities expire on September 30, 2026. Reauthorization bills introduced in the 119th Congress would extend the programs through fiscal year 2031.¹⁵ The fiscal year 2026 appropriations package included $90 million for ACT for ALS at NIH and a new $30 million ARPA-H investment in ALS research, and ALS organizations have asked Congress for at least $100 million for fiscal year 2027.¹⁴

A separate bill, the ALS Better Care Act, would adjust how Medicare pays for multidisciplinary clinic services, which is the mechanism most directly tied to the care model described in Section 4.¹⁴

Community organizations have an opening here. ACT for ALS reauthorization carries no partisan charge, and congressional offices weigh constituent contact heavily on bills of that kind.

The three programs below are proposals. None of them are operating yet, and each is scoped so that it could begin within ninety days of being funded.

Recognition outreach to the clinicians patients see first

The referral data points at a specific audience. Primary care physicians, physical therapists, and chiropractors are frequently the first professionals to examine someone with early ALS, and they are the ones deciding whether the next stop is neurology or orthopedics.

ALS Forward would develop a one-page recognition brief for practices across Central Indiana and the Chandler area covering the symptom patterns that should prompt a neurology referral. The goal is a clinical aid, not a continuing education course. Referral routing is the thing that needs to change, and a clinician who already knows what ALS looks like can still send a patient to the wrong specialist out of habit.

Measurement would come from tracking referral-to-diagnosis intervals at partner practices before and after distribution.

A navigation service between suspicion and specialist care

Families currently assemble their own referral chains during the period when they are least equipped to do it. A navigation service would hold current information on certified ALS clinic capacity and wait times across Indiana and Arizona. It would help families request records and place referrals, then follow up when one stalls, which is where most of the lost time accumulates.

The work is administrative, so trained volunteers or a part-time coordinator can do it without clinical licensure. Patient navigation programs in oncology have been shown to reduce time to treatment initiation. The ALS Association already runs an insurance navigator service for denials and appeals, and a local program should route families toward it instead of duplicating it.

Direct assistance for the costs nobody covers

Existing assistance programs are small relative to the need. The Hoffman ALS Financial Assistance Program, for instance, grants up to $1,000 per year for clinic-related expenses such as transportation, lodging, and copays. That is real help, and it is not close to sufficient against $17,889 in annual non-medical out-of-pocket costs.¹⁰

ALS Forward would establish a fund with a faster approval cycle than most existing programs. It would cover the expenses that stall care most often: vehicle modification, home accessibility work, and the weeks families spend waiting for ordered equipment to arrive while improvising with whatever is on hand.

Funding

Each of the three programs is scoped to run on its own, so a funder can support one without committing to the others. Full budgets, staffing assumptions, and year-one targets are available on request at info@alsforward.com.

Donate. Every dollar raised through ALS Forward events and giving pages funds the three programs in Section 8. Give at alsforward.com, or reach us at info@alsforward.com to discuss a directed or multi-year gift.

Contact Congress before September 30, 2026. ACT for ALS expires that day. Reauthorization bills are pending in both chambers, and constituent contact moves them. Find your representatives at congress.gov and tell them to reauthorize ACT for ALS and pass the ALS Better Care Act. This takes five minutes and costs nothing.

Partner with us clinically. Practices in and around Noblesville and Chandler willing to distribute the recognition brief and share de-identified referral timing data would let us measure whether it works instead of assuming it does. Write to info@alsforward.com.

Open a referral pathway. Health systems and certified ALS clinics can cut several weeks off the current process by agreeing to let a navigator route a suspected case straight into clinic intake.

Come to an event. Our calendar is at alsforward.com/events.

This paper draws on peer-reviewed literature indexed in PubMed, federal data from the CDC’s National ALS Registry, published cost analyses, and the text of pending congressional legislation. All sources were accessed through August 5, 2026 and are listed in Section 11.

Figures on diagnostic delay come from retrospective cohort studies and from one review covering twenty-one such studies. Estimates in this literature diverge, so the paper reports ranges instead of single numbers wherever the underlying studies disagree.

ALS Forward conducted no original research for this paper. The three programs described in Section 8 are proposals, and no outcome data exists for them yet. Cost figures come from national datasets and have not been adjusted for Indiana or Arizona, where what families actually pay may differ.